Table 2.

Efficacy end-points (%) at 30-day follow-up

	Eptifibatide*	Placebo	Absolute	Relative		Number needed
End-point	(n = 4722)	(n = 4739)	reduction	reduction	P	to treat
Death or infarction
Clinical events committee	14.2	15.7	1.5	9.6	0.042	10.4
Site investigator	8.1	10.0	1.9	19.0	0.0007	5.3
Myocardial infarction
Clinical events committee	12.6	13.6	1.0	7.4	0.137	13.5
Site investigator	6.2	7.8	1.6	20.5	0.002	4.9

^* High-dose group only.